Seikagaku To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatment In US

Seikagaku, a Tokyo company specializing in the study of intra-articular injection of hyaluronic acid, will begun conducting phase III clinical trials of Gel-200, a new hyaluronic acid gel for intra-articular injection in knee osteoarthritis patients, in the US in August.


The new gel is expected to have a highly analgesic effect with only one shot. In the US, Seikagaku has marketed injectable hyaluronic acid gel under the Supartz brand name since 2001, and currently claims a 20% share of the market.


Seikagaku hopes that the new drug will help expand its market share further since it requires just one injection compared with multiple injections required of Supartz.


The company will bring the new drug to market within four years.


By jcn, JCN Staff Writer


Copyright © 2006 JCN. All rights reserved. A division of Japan Corporate News Network KK.


JCN


View drug information on Supartz.